Conversations in Clinical Trial Disparities

Conversations in Clinical Trial Disparities

Conversations in Clinical Trial Disparities

How can you be sure about treatment if your patients are underrepresented in clinical trials? Learn how to increase trust to shift the balance.

Take Post-Survey

If you’ve already completed the activity.

  • Overview

    Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.  

  • Faculty Information

    Charles P. Vega, MD
    Clinical Professor, Family Medicine
    School of Medicine
    University of California, Irvine
    Orange, CA 

    Lionel Phillips, MBA
    President, Inside Edge Consulting Group
    103 College Road East, 2nd Fl.
    Princeton, NJ 08540

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the rationale for addressing racial and ethnic health disparities in clinical practice
    • Confidently reduce barriers to clinical trial access while increasing expertise about the need for diversity and inclusion in clinical trials
  • Target Audience

    This activity is designed to meet the educational needs of providers including physicians, nurse practitioners, physician assistants, and other healthcare professionals.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Pfizer.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free